PKD1/PKD2 Variant Sequencing for Early Polycystic Kidney Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating Polycystic Kidney Disease (PKD) are imprecise and often delayed, leading to inefficient use of medical resources and reduced quality of life for affected individuals, as they rely on symptom onset rather than early genetic variant detection.
Innovation Solution
A method that involves sequencing patients for qualifying variants in the PKD1 and PKD2 genes, combined with medical data such as hypertension and biomarker levels, to selectively recommend and trigger interventions, thereby identifying and treating PKD before symptom onset.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genetic sequencing for PKD1/PKD2 variants is implemented, then diagnostic precision and early detection capability are improved, but device complexity and cost increase
Solution Approach 1:
The patent performs genetic sequencing and identifies PKD1/PKD2 variants before symptoms of polycystic kidney disease manifest. By conducting the diagnostic action in advance (prenatally or in early childhood), the system achieves high diagnostic precision while allowing time for preventive interventions before the disease progresses to stages requiring complex treatment infrastructure.
2Duration of action of moving object
If early genetic detection and treatment is implemented, then quality of life and life expectancy are improved, but loss of time and resource allocation challenges worsen
Solution Approach 1:
The system implements early genetic detection through sequencing before symptom onset, enabling preventive treatment protocols to be initiated in utero or in early childhood. This preliminary action extends life expectancy by treating the disease at its earliest stage, while the standardized early intervention protocols actually reduce long-term time loss by preventing disease progression that would require more extensive future medical management.
3Productivity
If population-scale PKD screening is implemented, then productivity and resource efficiency are improved, but device complexity and infrastructure requirements worsen
Solution Approach 1:
The patent employs next-generation sequencing technology that serves multiple functions: it detects PKD1/PKD2 variants, identifies other genetic conditions simultaneously, and provides comprehensive genomic information for personalized medicine. This multi-functional approach improves resource efficiency by using a single diagnostic platform for multiple purposes, while the standardized nature of NGS technology actually reduces infrastructure complexity compared to implementing multiple separate diagnostic systems.
Data Source
AI summary
Systems and methods are provided for early intervention for PKD. One embodiment comprises a method for selectively recommending treatment for a patient for Polycystic Kidney Disease (PKD). The method includes reviewing sequencing data for the patient to determine if the patient has at least one qualifying variant in a gene PKD1 or a gene PKD2, the qualifying variant selected from the group consisting of Loss of Function (LoF) variants and coding variants. The method includes, if the patient does not have a qualifying variant in the gene PKD1 or the gene PKD2, generating a report recommending a first set of criteria for performing a PKD intervention. The method still further includes, if the patient does have a qualifying variant in the gene PKD1 or the gene PKD2, generating a report recommending a second set of criteria for performing the PKD intervention.